New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2013
04:55 EDTPFE, PFE, PFE, PFE, TEVA, TEVA, TEVA, TEVA, MYL, MYL, MYL, MYL, BASFY, BASFY, BASFY, BASFY, LLY, LLY, LLY, LLY, AMGN, AMGN, AMGN, AMGN, ABT, ABT, ABT, ABT, BIIB, BIIB, BIIB, BIIB, GSK, GSK, GSK, GSKDrug, Chemical & Associated Technologies Association to host conference
DCAT Week 2013 is being held in New York on March 11-14.
News For PFE;TEVA;MYL;BASFY;LLY;AMGN;ABT;BIIB;GSK From The Last 14 Days
Check below for free stories on PFE;TEVA;MYL;BASFY;LLY;AMGN;ABT;BIIB;GSK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
August 8, 2014
06:18 EDTGSKRoyal Bank of Scotland's Hampton leads race to become new GSK chair, FT reports
Royal Bank of Scotland (RBS) Chairman Philip Hampton is the frontrunner to succeed Christopher Gent as chairman of GlaxoSmithKline (GSK), the Financial Times reports, citing sources. Gent will step down from his role at GSK next year. Hampton is not expected to step down from RBS until after May's general election, the sources say. Reference Link
August 7, 2014
13:55 EDTTEVATeva won't be meaningfully hurt soon by new Copaxone filing, says BMO Capital
After Teva (TEVA) confirmed that it received the first paragraph IV notice for the 3x per week version of its Copaxone drug from Dr. Reddy's (RDY), BMO Capital said it had expected companies to seek to market a generic version of the latest Copaxone formulation, but was surprised that Dr. Reddy's took this action. The firm notes that Teva's decision to file a lawsuit against Dr. Reddy over the application will trigger a 30 month stay of approval of the generic version,. BMIO Capital says that investors should keep this issue on their radar, but the firm does not expect Teva to be meaningfully hurt in the near-term by this development. It keeps an Outperform rating on Teva.
12:06 EDTTEVATeva will continue to defend COPAXONE intellectual property rights
Teva (TEVA) confirmed that it has received the first paragraph IV notice for its three-times-a-week COPAXONE 40 mg/mL product from Dr. Reddy’s Laboratories (RDY). Teva will continue to vigorously defend its COPAXONE intellectual property rights against infringement wherever they are challenged. Teva intends to file a lawsuit for patent infringement against Dr. Reddy’s within the 45 day period provided under the Hatch-Waxman Act. The filing of the lawsuit will trigger a 30 month stay of FDA approval of Dr. Reddy’s ANDA. COPAXONE 40 mg/mL is protected by two Orange Book patents that expire in 2030.
10:51 EDTBIIBOptions with increasing implied volatility
Subscribe for More Information
10:29 EDTMYL, ABTMylan: Noise about inversion is tremendous speculation and that's all it is
Subscribe for More Information
10:23 EDTMYLMylan sees FY14 CapEx $350M-$400M
Subscribe for More Information
10:20 EDTMYLMylan sees FY14 adjusted EBITDA $2.2B-$2.4B
Subscribe for More Information
10:20 EDTMYL, TEVA, ABTMylan says litigation ins ongoing in India regarding Teva
Mylan (MYL) said that it expects Teva's (TEVA) efforts to seek an injunction will "as ineffective as it was in U.S. courts." The company said it will not provide further comment on the matter. Mylan said it will also postpone its 2014 Investor Day due to the ongoing nature of the Abbott (ABT) transaction. It expects its fully realized savings and profit from new products will not be realized till 2015. Comments taken from Q2 earnings conference call.
08:12 EDTPFEPfizer says EMA accpets application seeking new indication for Prevenar 13
Subscribe for More Information
06:42 EDTMYL, ABTObama to look to limit inversion deals, Politico says
Subscribe for More Information
06:37 EDTMYLMylan narrows FY14 adjusted EPS view to $3.25-$3.45 from $3.25-$3.60
Consensus $3.37. Narrows FY14 revenue guidance to $7.8B-$8B from $7.8B-$8.2B, consensus $7.77B.
06:36 EDTMYLMylan sees Q3 EPS 90c-95c, consensus $1.03
Subscribe for More Information
06:34 EDTMYLMylan reports Q2 adjusted EPS 69c, consensus 70c
Reports Q2 revenue $1.84B, consensus $1.88B.
August 6, 2014
15:49 EDTMYLNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Duke Energy (DUK), consensus 98c; Intercontinental Exchange (ICE), consensus $2.02; Mylan (MYL), consensus 70c; Scripps Networks (SNI), consensus $1.13; Brinker International (EAT), consensus 87; AES Corporation (AES), consensus 28c; NRG Energy (NRG), consensus 15c; Harman International (HAR), consensus $1.21; Windstream Holdings (WIN), consensus 8c; Teradata (TDC), consensus 65c; Markel (MKL), consensus $5.79; OGE Energy (OGE), consensus 51c; SunEdison (SUNE), consensus (28c); Royal Gold (RGLD), consensus 29c; Sabre (SABR), consensus 18c; Broadridge (BR), consensus $1.16; Huntington Ingalls (HII), consensus $1.81; AMC Networks (AMCX), consensus 85c; Laredo Petroleum (LPI), consensus 18c; HSN (HSNI), 77c; Wendy's (WEN), consensus 10c; Orbitz Worldwide (OWW), consensus 15c.
12:10 EDTPFEPfizer settles multi-state complaint on improper promotion of Rapamune
Attorney General Eric T. Schneiderman announced that he, along with 40 other state Attorneys General and the District of Columbia, reached a $35M settlement with Pfizer arising from alleged improper marketing and promotion of the immunosuppressive drug Rapamune. New York’s share of the settlement is over $1.7M. Pfizer, as parent of Wyeth Pharmaceuticals, agrees to be bound by the judgment and to resolve allegations that Wyeth unlawfully promoted Rapamune. Attorney General Schneiderman’s office served on the Executive Committee of this multi-state investigation. Reference Link
07:19 EDTBIIBAkebia names Brad Maroni as Chief Medical Officer
Akebia Therapeutics (AKBA) announced the expansion of its senior management team with three key additions: Brad Maroni, M.D., as Senior Vice President and Chief Medical Officer, Mark De Rosch, Ph.D., as Vice President of Regulatory Affairs and Tamara Dillon as Vice President of Human Resources. Maroni most recently served as Vice President, Medical Research at Biogen Idec (BIIB).
07:02 EDTGSKSynta Pharmaceuticals names Anne Whitaker as CEO, effective September 2
Subscribe for More Information
06:41 EDTABT, MYLObama administration may restrict inversion tax benefits, NY Times says
Subscribe for More Information
06:23 EDTPFEMitsubishi UFJ to hold a conference
Subscribe for More Information
06:21 EDTPFEPiper Jaffray to hold a summit
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use